Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people ...

Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December.

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

By developing drugs that act on the peripheral nervous system, Vertex aims to avoid the safety, tolerability, and addictive problems of drugs that act on the CNS. Vertex’s most advanced pain ...

Vertex Pharmaceuticals dominates the market for cystic fibrosis drugs, but Sionna Therapeutics contends the pharma company’s products still have efficacy and safety limitations. Sionna has ...

Vertex Pharma says its much-anticipated non-opioid painkiller, VX-548, clears two phase 3 trials en route to an FDA filing later this year. Vertex scores double win with non-opioid pain drug ...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. By Gina Kolata The Food and Drug Administration approved a new medication Thursday to treat ...

Vertex Pharmaceuticals Inc. ... The approval may signal regulatory confidence in the drug's efficacy and safety, which could drive adoption in a market where non-opioid options remain limited.

The FDA continues to monitor the drug's safety, effectiveness and quality. As Vertex Pharmaceuticals prepares to bring Journavx to market, the focus will be on educating healthcare providers and ...

Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive ...

Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be ...